NCT05988021View on ClinicalTrials.gov

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 3, 2015

Primary Completion Date

February 9, 2016

Study Completion Date

May 25, 2016

Conditions
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
DRUG

CCX168

Administered orally.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY